What is the latest DIVISLAB stock price?
The latest stored price for DIVISLAB is Rs 9,340.00 as of 2026-10-09.
gimli
DIVISLAB stock AI analysis
DIVISLAB Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
DIVI S LABORATORIES LTD is a large-cap stock in Healthcare. This Gimli page shows the latest available DIVISLAB price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹9,340.00
1W return
+0.98%
1M return
-1.56%
3M return
+37.09%
6M return
+56.91%
1Y return
+52.32%
Market cap
₹247,947.67 cr
PE
85.09
PB
14.79
ROE
+18.37%
ROCE
+11.06%
RSI
52.49
Turnover
₹353.86 cr
Why it can matter in screens
- Momentum: DIVISLAB is above 50DMA, above 200DMA; RSI is 52.49.
- Returns: 1D -0.22%, 1W +0.98%, 1M -1.56%, 3M +37.09%, 1Y +52.32%.
- Trend levels: 52W high ₹9,740.00, 52W low ₹6,450.50, off high -4.11%.
- Liquidity: latest turnover is ₹353.86 cr; volume vs 20D is +0.77%.
- Valuation/profitability: PE 85.09, PB 14.79, ROE +18.37%, ROCE +11.06%.
- Growth: 3Y sales CAGR +11.27%, 3Y profit CAGR +12.08%.
Quick Answers
Is DIVISLAB above its 50DMA and 200DMA?
DIVISLAB is above 50DMA, above 200DMA. The latest 50DMA is 9,004.83 and the latest 200DMA is 7,114.84.
What are DIVISLAB PE, ROE and ROCE?
DIVISLAB has PE 85.09, ROE +18.37%, and ROCE +11.06% in Gimli's latest available snapshot.
How has DIVISLAB performed recently?
DIVISLAB has returned -1.56% over 1 month, +37.09% over 3 months, and +52.32% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 3,037.00 cr | 1,303.00 cr | 891.00 cr | 33.55 |
| 2026-03-31 | 2,831.00 cr | 1,089.00 cr | 751.00 cr | 28.31 |
| 2025-12-31 | 2,604.00 cr | 904.00 cr | 583.00 cr | 21.98 |
| 2025-09-30 | 2,860.00 cr | 1,033.00 cr | 689.00 cr | 25.97 |
| 2025-06-30 | 2,410.00 cr | 848.00 cr | 545.00 cr | 20.49 |
| 2025-03-31 | 2,585.00 cr | 972.00 cr | 662.00 cr | 24.93 |
| 2024-12-31 | 2,319.00 cr | 825.00 cr | 589.00 cr | 22.20 |
| 2024-09-30 | 2,338.00 cr | 822.00 cr | 510.00 cr | 19.20 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 10,560.00 cr | 3,874.00 cr | 2,568.00 cr | 96.75 |
| 2025-03-31 | 9,360.00 cr | 3,320.00 cr | 2,191.00 cr | 82.53 |
| 2024-03-31 | 7,796.00 cr | 2,544.00 cr | 1,600.00 cr | 60.27 |
| 2023-03-31 | 7,665.00 cr | 2,712.00 cr | 1,824.00 cr | 68.69 |
| 2022-03-31 | 8,991.08 cr | 3,995.38 cr | 2,948.54 cr | 111.07 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 20,033.00 cr | 128.00 cr | 7.00 cr | 16,761.00 cr |
| 2025-03-31 | 16,932.00 cr | 415.00 cr | 4.00 cr | 14,969.00 cr |
| 2024-03-31 | 15,470.00 cr | 363.00 cr | 3.00 cr | 13,571.00 cr |
| 2023-03-31 | 14,439.00 cr | 170.00 cr | 4.00 cr | 12,767.00 cr |
| 2022-03-31 | 13,374.71 cr | 1,214.76 cr | 3.69 cr | 11,728.18 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 2,738.00 cr | 218.00 cr | n/a |
| 2025-03-31 | 1,653.00 cr | 215.00 cr | n/a |
| 2024-03-31 | 1,261.00 cr | 258.00 cr | n/a |
| 2023-03-31 | 2,459.00 cr | 1,986.00 cr | n/a |
| 2022-03-31 | 1,911.80 cr | 1,198.60 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +51.88% | +20.20% | +19.38% | +13.87% | +8.54% | +0.00% |
| 2026-03-31 | +51.88% | +20.29% | +19.22% | +13.42% | +8.60% | +0.00% |
| 2025-12-31 | +51.88% | +20.08% | +19.28% | +13.73% | +8.76% | +0.00% |
| 2025-09-30 | +51.89% | +19.39% | +19.76% | +13.99% | +8.96% | +0.00% |
| 2025-06-30 | +51.89% | +19.74% | +19.05% | +13.31% | +9.32% | +0.00% |
| 2025-03-31 | +51.89% | +18.01% | +20.71% | +12.83% | +9.39% | +0.00% |
| 2024-12-31 | +51.89% | +17.99% | +20.54% | +11.89% | +9.58% | +0.00% |
| 2024-09-30 | +51.89% | +17.25% | +21.06% | +11.92% | +9.80% | +0.00% |
| 2024-06-30 | +51.90% | +16.16% | +21.77% | +13.10% | +10.18% | +0.00% |
| 2024-03-31 | +51.92% | +14.68% | +22.21% | +14.28% | +11.19% | +0.00% |
| 2023-12-31 | +51.92% | +14.86% | +21.88% | +13.72% | +11.33% | +0.00% |
| 2023-09-30 | +51.93% | +14.60% | +21.75% | +13.62% | +11.72% | +0.00% |
| 2023-06-30 | +51.93% | +14.70% | +21.23% | +13.20% | +12.14% | +0.00% |
| 2023-03-31 | +51.94% | +14.67% | +21.07% | +13.15% | +12.31% | +0.00% |
| 2022-12-31 | +51.94% | +15.15% | +20.67% | +12.68% | +12.24% | +0.00% |
| 2022-09-30 | +51.94% | +15.40% | +20.78% | +13.62% | +11.87% | +0.00% |
| 2022-06-30 | +51.94% | +0.00% | +36.50% | n/a | n/a | +0.00% |
| 2022-03-31 | +51.94% | +0.00% | +36.77% | n/a | n/a | +0.00% |
| 2021-12-31 | +51.95% | +0.00% | +37.03% | n/a | n/a | +0.00% |
| 2021-09-30 | +51.95% | +0.00% | +37.06% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 422,282.96 cr | 34.857273 | +15.50% | +6.12% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,610.64 cr | 72.265309 | +17.33% | +31.16% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 115,423.17 cr | 58.937484 | +21.03% | +4.32% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,446.65 cr | 25.058308 | +16.04% | +12.37% |
| LAURUSLABS | LAURUS LABS LIMITED | 109,947.20 cr | 100.670416 | +21.77% | +135.42% |
| CIPLA | CIPLA LTD | 105,094.85 cr | 31.162389 | +10.25% | -14.02% |
| DRREDDY | DR. REDDY S LABORATORIES | 99,661.60 cr | 30.096514 | +9.23% | -3.94% |
| MANKIND | MANKIND PHARMA LIMITED | 97,778.38 cr | 47.665615 | +13.18% | -4.47% |
Try these prompts
- Analyze DIVI S LABORATORIES with valuation, momentum and industry peers
- Compare DIVISLAB with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare DIVISLAB with other Healthcare stocks
Data snapshot: 2026-10-09. Not investment advice.